Riley Polk

Brigham Exploration Co. is an independent exploration, development and production company. The company engages in the exploration and development of onshore crude oil and natural gas reserves. Its exploration and production activities are performed primarily in the onshore Texas Gulf Coast, the Anadarko Basin of northwest Oklahoma, the Texas Panhandle and west Texas. Brigham Exploration was founded by Ben M. Brigham in 1990 and is headquartered in Austin, TX.

Gas Turbine Efficiency Ltd. designs, manufactures and supplies proprietary cleantech energy saving and performance enhancing solutions. The company was founded on March 17, 2005 by Peter Asplund and is headquartered in London, the United Kingdom.

Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX.

Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY.

Diagnostic Hybrids, Inc. develops, manufactures and markets cellular and molecular diagnostic kits. Its products include rapid diagnostics, thyroid testing solutions, respiratory family testing, herpes family testing, chlamydia testing, enterovirus testing, cell lines and media and supplements. The company was founded by Wilfred R. Konneker, Joseph Jollick and Thomas E. Wagner in 1983 and is headquartered in Athens, OH.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

The American Association of Pharmaceutical Scientists engages in research and development of pharmaceutical products. The private company is based in Arlington, VA. The company was founded by Leslie Z. Benet.

The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus.

Enavail LLC produces bioactive peptides and compounds for clinical research. Its technology focuses on generating crystalline or amorphous forms of poorly water-soluble compounds, providing enhanced dissolution and bioavailability, and producing powder forms of labile proteins. The company was founded in 2009 and is headquartered in Austin, TX.

Brooke Army Medical Center provides health care services for military members. The private company is based in Houston, TX.

Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno.

Anthem Ventures LLC is an investment firm that primarily invests in early stage series A technology companies. The private company is based in Austin, TX. The company is active investors who often lead or co-lead and take a board seat. The company's focus is on supporting and growing innovative startups. The company was founded by Ben M. Brigham.

LumaBridge LLC is an oncology clinical research organization that offers comprehensive clinical research organization services, customized trials, and pioneering experience in immuno-oncology. The company is based in San Antonio, TX. The company's mission is to bring life-changing therapies to patients cost-effectively. LumaBridge has a huge network of research sites and offers innovative trial solutions and partnerships. LumaBridge was founded in 2014 by George E. Peoples and Daniel L. Hargrove, and the CEO is J. David Boyle.

Walter Reed Army Medical Center is a general hospital located in Bethesda. The American company operates as a medical center providing healthcare services to patients.

Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA.

Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million.